Fidaxomicin
| Title | Journal |
|---|---|
| Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Fidaxomicin inhibits spore production in Clostridium difficile. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| New drugs 2012, part 2. | Nursing 20120701 |
| Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120601 |
| Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies. | Future microbiology 20120601 |
| Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. | The Lancet. Infectious diseases 20120401 |
| Progress with a difficult infection. | The Lancet. Infectious diseases 20120401 |
| Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120215 |
| Annual drug update: 2011 in review. | The Nurse practitioner 20120212 |
| Clostridium difficile infection in older adults: a review and update on its management. | The American journal of geriatric pharmacotherapy 20120201 |
| Fidaxomicin for the treatment of Clostridium difficile infections. | The Annals of pharmacotherapy 20120201 |
| Fidaxomicin, a new treatment for Clostridium difficile infections. | Drugs of today (Barcelona, Spain : 1998) 20120201 |
| Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. | Clinical therapeutics 20120101 |
| Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. | Clinical drug investigation 20120101 |
| Fidaxomicin: in Clostridium difficile infection. | Drugs 20111224 |
| Comparative effectiveness of Clostridium difficile treatments: a systematic review. | Annals of internal medicine 20111220 |
| Clostridium difficile infection: clinical spectrum and approach to management. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20111201 |
| Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110901 |
| Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. | Pharmacotherapy 20110901 |
| Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. | Journal of medical microbiology 20110801 |
| Characterization of a sugar-O-methyltransferase TiaS5 affords new Tiacumicin analogues with improved antibacterial properties and reveals substrate promiscuity. | Chembiochem : a European journal of chemical biology 20110725 |
| Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20110701 |
| Fidaxomicin: first-in-class macrocyclic antibiotic. | Expert review of anti-infective therapy 20110701 |
| Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin. | Managed care (Langhorne, Pa.) 20110701 |
| Fidaxomicin for Clostridium difficile Infection. | The New England journal of medicine 20110512 |
| Fidaxomicin for Clostridium difficile infection. | The New England journal of medicine 20110512 |
| Fidaxomicin versus vancomycin for Clostridium difficile infection. | The New England journal of medicine 20110203 |
| The search for effective treatment of Clostridium difficile infection. | The New England journal of medicine 20110203 |
| Characterization of tiacumicin B biosynthetic gene cluster affording diversified tiacumicin analogues and revealing a tailoring dihalogenase. | Journal of the American Chemical Society 20110202 |
| 'Game changer' antibiotic and others in works for superbug. | Nature medicine 20110101 |
| Rivaroxaban, ticagrelor, and fidaxomicin. | Journal of the American Pharmacists Association : JAPhA 20110101 |
| Management of Clostridium difficile infection: thinking inside and outside the box. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101201 |
| A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. | Microbiology (Reading, England) 20101101 |
| New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. | Expert opinion on therapeutic patents 20101001 |
| Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. | Expert opinion on pharmacotherapy 20100601 |
| Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. | Expert review of anti-infective therapy 20100501 |
| Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. | Future microbiology 20100401 |
| Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. | Journal of ethnopharmacology 20090706 |
| Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. | The Journal of antimicrobial chemotherapy 20081001 |